Haemoglobinopathies particularly haemoglobin S and E (HbS, HbE) and β-thalassaemia are important challenges for tribal populations in India. The HbS, HbE and β-thalassaemia genes are variably distributed across various tribal populations of India. HbE is mainly restricted in tribals of North-East, West Bengal, Odisha and those in Andaman and Nicobar islands. HbS has more extensive distribution in the country (10-40% trait frequency) and the homozygotes and double heterozygotes present with a wide array of morbidities. the morbidity varies greatly in different areas of the country due to differential co-inheritance of α-thalassaemia gene and interaction of various epistatic and environmental factors. Though substantial data on prevalence of these disorders exist, there is an urgent need to develop integrated hierarchical core facilities to manage the disease. Such centres will generate more data and will also explore areas of management which need more local attention. Newborn screening, genetic counselling, carrier detection, prenatal diagnosis along with management of cases should form the basic infrastructure of haemoglobinopathy management. Research in this areas should continue focusing on various challenges in care delivery, prevention and basic sciences on interaction of haemoglobinopathies with various other infections.
Tribal population of India constitutes approximately 8.5 per cent of the total population of India 1 . Tribal population in India is not a homogenous group. Further, because of their isolated existence and endogamy over centuries, different tribal populations have distinctive genetic identities. With industrialization and availability of jobs in different areas of India many of these tribal populations have migrated from their homelands to cities in search of jobs. Although these migrations are relatively in small proportions (5-10%) but the absolute number of tribal persons living in big cities and industrialized areas of the country is substantial 2 .
Why is this information important when we discuss haemoglobinopathies in tribal populations of India? The answer lies in deciding whether to provide haemoglobinopathy care only in the tribal belts of India or whether it should be broad-based across the length and breadth of the country. These tribals can be broadly divided into several groups (i) One of the arguments after describing this broad spectrum of haemoglobinopathies in India is that we still have a long way to go as we have not micromapped the prevalence of HbS across the country and this is needed to develop a clear picture of HbS prevalence in each of the >400 tribal populations of India. However, we have done these prevalence studies from late 1950s and a reasonable amount of data show that sickle haemoglobin is a major problem in the country and the recent migration of tribals across the metropolis to 1-and 2-tier cities in search of livelihood also suggests that geography of haemoglobinopathy in both tribal and non-tribal populations in this country is changing. Though α-thalassaemia gene is prevalent across the country and on the average 14 per cent of the Indian population carry this gene 21 . Deletional α-thalassaemia in India in general does not produce a large number of HbH disease cases 22 and this condition is largely asymptomatic or mild except for producing microcytosis. This microcytosis is important in the differential diagnosis of β-thalassaemia syndromes and sickle cell disease, hence directly α-thalassaemias are not really a clinical challenge.
One of the major deficits in the studies of haemoglobinopathies in India among tribal populations is (i) lack of integrated hierarchical management and diagnostic facilities for haemoglobinopathies in remote areas where majority of the tribal populations reside, and (ii) lack of a haemoglobinopathy registry for the country as this would be a major tool for the State and central governments to concentrate efforts to develop facilities for care and diagnosis where they are needed most.
The primary health centres, rural hospitals and Taluka hospitals located in tribal areas of the country need additional strengthening for immediate management of sickle cell related clinical conditions through intravenous fluid therapy, pain relief, regular supply of folic acid tablets and referring more complicated patients (chest syndrome, pregnancy, strokes and other complications) to district hospitals, and finally to other tertiary care centres where facilities for management of such cases are available. These facilities need extra manpower, space, instruments which should be urgently provided.
Genetic counselling forms an important component in the management of such disorders 23 . Non-governmental organizations (NGOs) with patient groups can take over some of the burden of counselling.
Apart from adequate hydration, pain relief, folic acid supplementation, adequate nutrition, personal protection from extreme weather conditions, prompt treatment for infection and diarrhoeal disorders, low dose hydroxyurea therapy have been shown to be safe and significantly reduce pain and improve quality of life in sickle cell anaemia patients 24, 25 . Hydroxyurea has also been shown to be effective in <30 per cent patients with β-thalassaemia major and >70 per cent of patients of thalassaemia intermedia 26 .
Several centres in India are engaged in haemoglobinopathy research in tribal areas. Certain key areas are being looked at or need to be looked at in future with a view to better understand the disease in the Indian context. These areas are: (i) newborn screening for haemoglobinopathies in tribal areas; (ii) Follow up of newborn cohorts in a multicentric fashion for atleast five years to understand the nature of early mortality and morbidity in these populations; (iii) Developing a registry on haemoglobinopathies for tribal populations; (iv) Study the interaction of gastrointestinal parasitism, iron deficiency, nutritional intake with haemoglobinopathies and finally deciding whether these components should be routinely assessed and what remedial measures should be undertaken; (v) Evaluation of various ethno-pharmacological products for management of the condition; (vi) Prevalence and cause of hypersplenism in sickle cell anaemia patients in tribals; (vii) Interaction of various genetic factors for epistatic interaction in modulation of the disease; (viii) Interaction of malarial infection with haemoglobinopathy; and (ix) Prenatal diagnosis for severe haemoglobinopathies.
As the centres managing haemoglobinopathies in tribals increase their experience, more and more families with this condition will come forward and cascade screening and counselling of these families will provide additional cases and carriers, and this will also provide newer area for research.
